Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657 - PubMed (original) (raw)
Multicenter Study
. 2012 Sep 10;30(26):3242-9.
doi: 10.1200/JCO.2011.39.2779. Epub 2012 May 29.
Donald A Berry, Angela DeMichele, Lisa Carey, Sarah E Davis, Meredith Buxton, Cliff Hudis, Joe W Gray, Charles Perou, Christina Yau, Chad Livasy, Helen Krontiras, Leslie Montgomery, Debasish Tripathy, Constance Lehman, Minetta C Liu, Olufunmilayo I Olopade, Hope S Rugo, John T Carpenter, Lynn Dressler, David Chhieng, Baljit Singh, Carolyn Mies, Joseph Rabban, Yunn-Yi Chen, Dilip Giri, Laura van 't Veer, Nola Hylton
Affiliations
- PMID: 22649152
- PMCID: PMC3434983
- DOI: 10.1200/JCO.2011.39.2779
Multicenter Study
Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657
Laura J Esserman et al. J Clin Oncol. 2012.
Abstract
Purpose: Neoadjuvant chemotherapy for breast cancer provides critical information about tumor response; how best to leverage this for predicting recurrence-free survival (RFS) is not established. The I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) was a multicenter breast cancer study integrating clinical, imaging, and genomic data to evaluate pathologic response, RFS, and their relationship and predictability based on tumor biomarkers.
Patients and methods: Eligible patients had tumors ≥ 3 cm and received neoadjuvant chemotherapy. We determined associations between pathologic complete response (pCR; defined as the absence of invasive cancer in breast and nodes) and RFS, overall and within receptor subsets.
Results: In 221 evaluable patients (median tumor size, 6.0 cm; median age, 49 years; 91% classified as poor risk on the basis of the 70-gene prognosis profile), 41% were hormone receptor (HR) negative, and 31% were human epidermal growth factor receptor 2 (HER2) positive. For 190 patients treated without neoadjuvant trastuzumab, pCR was highest for HR-negative/HER2-positive patients (45%) and lowest for HR-positive/HER2-negative patients (9%). Achieving pCR predicted favorable RFS. For 172 patients treated without trastuzumab, the hazard ratio for RFS of pCR versus no pCR was 0.29 (95% CI, 0.07 to 0.82). pCR was more predictive of RFS by multivariate analysis when subtype was taken into account, and point estimates of hazard ratios within the HR-positive/HER2-negative (hazard ratio, 0.00; 95% CI, 0.00 to 0.93), HR-negative/HER2-negative (hazard ratio, 0.25; 95% CI, 0.04 to 0.97), and HER2-positive (hazard ratio, 0.14; 95% CI, 0.01 to 1.0) subtypes are lower. Ki67 further improved the prediction of pCR within subsets.
Conclusion: In this biologically high-risk group, pCR differs by receptor subset. pCR is more highly predictive of RFS within every established receptor subset than overall, demonstrating that the extent of outcome advantage conferred by pCR is specific to tumor biology.
Conflict of interest statement
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.
Figures
Fig 1.
I-SPY 1 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) schema. Sixteen-gauge core-needle biopsies were performed at four time points: T1, before treatment; T2, between 24 and 96 hours after starting treatment; T3, after completing the regimen that contained doxorubicin (if a taxane was to be given); and T4, at the time of surgical resection. Blood was drawn to obtain serum and plasma before chemotherapy, between anthracycline and taxane regimens, if applicable, and before surgery. Magnetic resonance (MR) images were obtained before chemotherapy, approximately 2 weeks after the first dose of anthracycline, at the end of anthracycline treatment (if the patient went on to receive a taxane), and again before surgical resection. The goal of the trial was to relate early and late outcomes. Early outcome measures included MR volume change and rates of pathologic complete response (pCR). Late outcomes were measured by recurrence-free survival (RFS), which was measured as the proportion of patients who did not experience an invasive breast cancer recurrence in the ipsilateral breast or regional nodes, distant organ sites, or death from any cause for the specified time period. MRI, magnetic resonance imaging. (*) Twenty-four to 96 hours after the start of anthracycline. (†) Two weeks after the start of anthracycline.
Fig 2.
I-SPY 1 (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging and Molecular Analysis) CONSORT diagram. Of the 237 patients enrolled, 221 patients were evaluable, 215 had pathology results, and 210 had receptor data available. HER2, human epidermal growth factor receptor; HR, hormone receptor. (*) No. of patients who did not receive neoadjuvant trastuzumab. Trastuzumab was approved for use during the last year of study enrollment and was available to HER2-positive patients after that time. (†) No. of patients who did not receive any trastuzumab.
Fig 3.
Recurrence-free survival stratified by pathologic complete response (pCR) for the overall population (left side) of patients (excluding all patients treated with trastuzumab; n = 38) and (right side) by hormone receptor (HR) –positive/human epidermal growth factor receptor 2 (HER2) –negative, HR-negative/HER2-negative (triple negative), and HER2-positive subsets.
Similar articles
- The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.
Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P. Sánchez-Muñoz A, et al. Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11. Clin Breast Cancer. 2013. PMID: 23318089 Clinical Trial. - Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N; I-SPY 1 TRIAL Investigators. Esserman LJ, et al. Breast Cancer Res Treat. 2012 Apr;132(3):1049-62. doi: 10.1007/s10549-011-1895-2. Epub 2011 Dec 25. Breast Cancer Res Treat. 2012. PMID: 22198468 Free PMC article. - Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA. Caudle AS, et al. Breast Cancer Res. 2012 May 23;14(3):R83. doi: 10.1186/bcr3198. Breast Cancer Res. 2012. PMID: 22621334 Free PMC article. - Survival after neoadjuvant therapy with trastuzumab-lapatinib and chemotherapy in patients with HER2-positive early breast cancer: a meta-analysis of randomized trials.
Guarneri V, Griguolo G, Miglietta F, Conte PF, Dieci MV, Girardi F. Guarneri V, et al. ESMO Open. 2022 Apr;7(2):100433. doi: 10.1016/j.esmoop.2022.100433. Epub 2022 Mar 8. ESMO Open. 2022. PMID: 35276440 Free PMC article. Review. - Neoadjuvant treatment of HER2 and hormone-receptor positive breast cancer - moving beyond pathological complete response.
Di Cosimo S, Arpino G, Generali D. Di Cosimo S, et al. Breast. 2014 Apr;23(2):188-92. doi: 10.1016/j.breast.2013.12.005. Epub 2014 Jan 4. Breast. 2014. PMID: 24393616 Review.
Cited by
- In-Breast Tumor Progression During Neoadjuvant Chemotherapy: Impact on and Factors Influencing Distant Recurrence-Free Survival.
Eckert KM, Hoskin TL, Olson CA, Goetz MP, Boughey JC. Eckert KM, et al. Ann Surg Oncol. 2024 Sep 12. doi: 10.1245/s10434-024-16178-9. Online ahead of print. Ann Surg Oncol. 2024. PMID: 39266789 - A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance.
Sinevici N, Edmonds CE, Dontchos BN, Wang G, Lehman CD, Isakoff S, Mahmood U. Sinevici N, et al. Breast Cancer Res. 2024 Jun 29;26(1):107. doi: 10.1186/s13058-024-01859-w. Breast Cancer Res. 2024. PMID: 38951909 Free PMC article. - Predictive analysis of breast cancer response to neoadjuvant chemotherapy through plasma metabolomics.
Yamada M, Jinno H, Naruse S, Isono Y, Maeda Y, Sato A, Matsumoto A, Ikeda T, Sugimoto M. Yamada M, et al. Breast Cancer Res Treat. 2024 Sep;207(2):393-404. doi: 10.1007/s10549-024-07370-2. Epub 2024 May 13. Breast Cancer Res Treat. 2024. PMID: 38740665 - Early evaluation of circulating tumor DNA as marker of therapeutic efficacy and prognosis in breast cancer patients during primary systemic therapy.
Wang R, Wang B, Zhang H, Liao X, Shi B, Zhou Y, Zhou C, Yan Y, Zhang W, Wang K, Ge G, Ren Y, Tang X, Gan B, He J, Niu L. Wang R, et al. Breast. 2024 Aug;76:103738. doi: 10.1016/j.breast.2024.103738. Epub 2024 Apr 24. Breast. 2024. PMID: 38685149 Free PMC article. - Mammographic assessment of breast density as a tool for predicting the response to neoadjuvant therapy in breast cancer patients.
Lisencu LA, Roman A, Paşca A, Irimie A, Lisencu C, Negrutiu M, Fetica B, Cismaru A, Balacescu O, Tudoran O, Lisencu C. Lisencu LA, et al. Med Pharm Rep. 2024 Jan;97(1):43-55. doi: 10.15386/mpr-2554. Epub 2024 Jan 29. Med Pharm Rep. 2024. PMID: 38344331 Free PMC article.
References
- Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353:1784–1792. - PubMed
- Hser YI. Self-reported drug use: Results of selected empirical investigations of validity. NIDA Res Monogr. 1997;167:320–343. - PubMed
- Valero VV, Buzdar AU, Hortobagyi GN. Locally advanced breast cancer. Oncologist. 1996;1:8–17. - PubMed
- Esserman LJ, van 't Veer LJ, Perou C, et al. Biology of breast cancers that present as interval cancers and at young age should inform how we approach early detection and prevention. Cancer Res. 2009;69(suppl 2; abstr 6034)
- Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–2334. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA33601/CA/NCI NIH HHS/United States
- P30 CA016672/CA/NCI NIH HHS/United States
- CA58207/CA/NCI NIH HHS/United States
- U01 CA080098/CA/NCI NIH HHS/United States
- U10 CA033601/CA/NCI NIH HHS/United States
- U10 CA079778/CA/NCI NIH HHS/United States
- P50 CA058223/CA/NCI NIH HHS/United States
- P50 CA058207/CA/NCI NIH HHS/United States
- U01 CA079778/CA/NCI NIH HHS/United States
- CA079778/CA/NCI NIH HHS/United States
- U10 CA080098/CA/NCI NIH HHS/United States
- CA31964/CA/NCI NIH HHS/United States
- CA080098/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous